PureTech Health PLC (PRTC)Healthcare | Biotechnology | Boston, United States |
USD
|
Hot Take ↕ | Aug. 22, 2026, 6 a.m. UTC
The immediate outlook is severely compromised by a lack of directional momentum and a critical delisting event. With the company announcing an intention to voluntarily delist its American Depositary Shares from Nasdaq to concentrate trading on the London Stock Exchange, liquidity risks and access friction are likely to increase for US investors. Technically, the stock is trapped between its 50-day and 200-day averages, showing no breakout potential, while volume remains below average. Fundamentally, the business is deteriorating rapidly with a 38% decline in revenue, negative operating margins of nearly 18%, and massive free cash outflows exceeding $89 million. The valuation metrics are distorted by losses, showing a negative forward P/E and an enterprise-to-revenue multiple of nearly 890x, indicating the market has priced in significant distress. Without a clear path to profitability or a catalyst to reverse the revenue slide, the investment case is currently non-existent. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 66.494 |
| Revenue per Share | 0.19 |
| Market Cap | 424,034,496 |
| Forward P/E | -34.84 |
| Beta | 0.79 |
| Website | https://www.puretechhealth.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.002178669 |
| Address1 | 6 Tide Street |
| Address2 | Suite 400 |
| All Time High | 65.9 |
| All Time Low | 13.3 |
| Ask | 15.7 |
| Ask Size | 100 |
| Average Daily Volume10 Day | 7,828 |
| Average Volume | 9,189 |
| Average Volume10Days | 7,828 |
| Beta | 0.788 |
| Bid | 17.89 |
| Bid Size | 100 |
| Book Value | 12.91 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Currency | USD |
| Current Price | 17.42 |
| Current Ratio | 6.587 |
| Date Short Interest | 1,777,507,200 |
| Day High | 17.25 |
| Day Low | 17.25 |
| Debt To Equity | 66.494 |
| Ebitda | -96,830,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -42.793 |
| Enterprise To Revenue | 889.38 |
| Enterprise Value | 4,143,619,584 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fax | 617 482 3337 |
| Fifty Day Average | 16.935312 |
| Fifty Two Week High | 19.92 |
| Fifty Two Week Low | 14.5 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,295,000 |
| Float Shares | 157,179,994 |
| Forward Eps | -0.5 |
| Forward P E | -34.84 |
| Free Cashflow | -89,990,376 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -51,796,000 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.0057599996 |
| Implied Shares Outstanding | 24,341,819 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts. |
| Long Name | PureTech Health PLC |
| Market Cap | 424,034,496 |
| Max Age | 86,400 |
| Message Board Id | finmb_9240598 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -109,739,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 384,487,404 |
| Open | 17.435 |
| Operating Cashflow | -85,131,000 |
| Operating Margins | -17.97792 |
| Payout Ratio | 0.0 |
| Phone | 617 482 2333 |
| Previous Close | 17.25 |
| Price Hint | 2 |
| Price To Book | 1.3493416 |
| Price To Sales Trailing12 Months | 91.01406 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.41 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 17.25 |
| Regular Market Day Low | 17.25 |
| Regular Market Open | 17.435 |
| Regular Market Previous Close | 17.25 |
| Regular Market Volume | 6,761 |
| Return On Assets | -0.10816 |
| Return On Equity | -0.30853 |
| Revenue Growth | -0.382 |
| Revenue Per Share | 0.19 |
| Sand P52 Week Change | 0.20282328 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 24,341,819 |
| Shares Percent Shares Out | 0.001 |
| Shares Short | 24,521 |
| Shares Short Previous Month Date | 1,774,915,200 |
| Shares Short Prior Month | 14,823 |
| Short Name | PureTech Health plc |
| Short Percent Of Float | 0.0011999999 |
| Short Ratio | 3.94 |
| State | MA |
| Symbol | PRTC |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 288,716,000 |
| Total Cash Per Share | 1.186 |
| Total Debt | 203,256,000 |
| Total Revenue | 4,659,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.6 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 17.20925 |
| Underlying Symbol | PRTC |
| Uuid | b3befbc5-de9a-359f-ae02-9ade770a8642 |
| Volume | 6,761 |
| Website | https://www.puretechhealth.com |
| Zip | 2,210 |